J G Jurcic

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Immunotherapy for acute myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 458, New York, NY 10021, USA
    Curr Oncol Rep 7:339-46. 2005
  2. doi What happened to anti-CD33 therapy for acute myeloid leukemia?
    Joseph G Jurcic
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Hematol Malig Rep 7:65-73. 2012
  3. ncbi Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches
    J G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
    Curr Opin Hematol 7:247-54. 2000
  4. ncbi Ab therapy of AML: native anti-CD33 Ab and drug conjugates
    J G Jurcic
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, New York, USA
    Cytotherapy 10:7-12. 2008
  5. ncbi Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
  6. ncbi Diagnosis and treatment of acute promyelocytic leukemia
    Joseph G Jurcic
    Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 9:337-44. 2007
  7. ncbi Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia
    J G Jurcic
    Leukemia, Hematology, and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 98:2651-6. 2001
  8. ncbi Antibody therapy for residual disease in acute myelogenous leukemia
    J G Jurcic
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Crit Rev Oncol Hematol 38:37-45. 2001
  9. ncbi Antibody immunotherapy for leukemia
    J G Jurcic
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 2:114-22. 2000
  10. ncbi Antibody therapy of acute myelogenous leukemia
    J G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Biother Radiopharm 15:319-26. 2000

Collaborators

Detail Information

Publications30

  1. ncbi Immunotherapy for acute myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 458, New York, NY 10021, USA
    Curr Oncol Rep 7:339-46. 2005
    ..T-cell recognition of peptide antigens presented on the cell surface in combination with major histocompatibility complex antigen provides another potentially promising approach for the treatment of AML...
  2. doi What happened to anti-CD33 therapy for acute myeloid leukemia?
    Joseph G Jurcic
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Hematol Malig Rep 7:65-73. 2012
    ....
  3. ncbi Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches
    J G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
    Curr Opin Hematol 7:247-54. 2000
    ..Clinical trials exploiting the new understanding of the T cell immunology are underway...
  4. ncbi Ab therapy of AML: native anti-CD33 Ab and drug conjugates
    J G Jurcic
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, New York, USA
    Cytotherapy 10:7-12. 2008
    ....
  5. ncbi Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
    ..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans...
  6. ncbi Diagnosis and treatment of acute promyelocytic leukemia
    Joseph G Jurcic
    Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 9:337-44. 2007
    ..The lessons learned from APL have broad applications to other forms of leukemia and to cancer in general, whereby molecularly targeted therapy is directed to specifically defined subgroups...
  7. ncbi Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia
    J G Jurcic
    Leukemia, Hematology, and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 98:2651-6. 2001
    ..Conversely, a confirmed positive test is highly predictive of relapse...
  8. ncbi Antibody therapy for residual disease in acute myelogenous leukemia
    J G Jurcic
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Crit Rev Oncol Hematol 38:37-45. 2001
    ..Antibody-drug conjugates, such as gemtuzumab ozogamicin, composed of a humanized anti-CD33 mAb and calicheamicin, have produced complete remissions in patients with relapsed AML and are likely to be active in the postremission setting...
  9. ncbi Antibody immunotherapy for leukemia
    J G Jurcic
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 2:114-22. 2000
    ..Targeted alpha particle therapy offers the possibility of selective tumor cell kill while sparing surrounding normal cells. Antibody-drug conjugates and immunotoxins have produced complete remissions in leukemia...
  10. ncbi Antibody therapy of acute myelogenous leukemia
    J G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Biother Radiopharm 15:319-26. 2000
    ..Additionally, directed chemotherapy using an anti-CD33-calicheamicin conjugate (CMA-676) has produced remissions in patients with relapsed AML...
  11. ncbi Monitoring PML-RARalpha in acute promyelocytic leukemia
    Joseph G Jurcic
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 5:391-8. 2003
    ..APL provides a useful model in which therapy is targeted to an underlying genetic aberration and treatment is adapted based on monitoring of residual disease...
  12. ncbi Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia
    K S Kolbert
    Department of Medical Physics Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 42:27-32. 2001
    ..CONCLUSION: Rate images make it possible to succinctly display kinetic information about an agent's behavior over the entire acquired image...
  13. ncbi Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias
    J M Burke
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY, USA
    Bone Marrow Transplant 32:549-56. 2003
    ..These studies show the feasibility of adding CD33-targeted radioimmunotherapy to a standard BMT preparative regimen; however, randomized trials will be needed to prove a benefit to intensified conditioning with radioimmunotherapy...
  14. pmc Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses
    Nicole Lamanna
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:491-7. 2009
    ..In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R)...
  15. ncbi Monoclonal antibody therapy of APL
    P G Maslak
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr Top Microbiol Immunol 313:205-19. 2007
    ..The preliminary results have been promising, and further development of this modality as an effective adjunct to existing treatment regimens will most certainly occur in the near future...
  16. ncbi Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia
    Mark A Weiss
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 21:1278-84. 2003
    ..Of the purine analogs active in CLL, pentostatin may be least myelosuppressive. We hypothesized that combining pentostatin with cyclophosphamide would have less myelotoxicity than combinations using other purine analogs...
  17. ncbi Radioimmunotherapy for acute leukemia
    John M Burke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Control 9:106-13. 2002
    ..In this article, we summarize the role of radioimmunotherapy in the treatment of leukemia...
  18. ncbi The promise of targeted {alpha}-particle therapy
    Deborah A Mulford
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:199S-204S. 2005
    ..Treatment of patients with less-advanced disease and, ultimately, randomized trials comparing targeted alpha-particle therapy with standard approaches will be required to determine the clinical utility of this approach...
  19. doi Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
    ..In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity...
  20. ncbi Acute myeloid leukemia with t(5;18)(q35;q21)
    E S Wang
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Cancer Genet Cytogenet 127:71-3. 2001
    ..Possible molecular mechanisms underlying the pathogenesis of the disease are discussed...
  21. ncbi Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Nicole Lamanna
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1575-81. 2006
    ..We previously reported that pentostatin and cyclophosphamide (PC) is active and well-tolerated in patients with relapsed or refractory CLL. Subsequently, we added rituximab, and now report on this three-drug combination...
  22. ncbi Radioimmunotherapy of leukemia
    John M Burke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NewYork 10021, USA
    Adv Pharmacol 51:185-208. 2004
  23. ncbi Antibody-based treatment of acute myeloid leukaemia
    Deborah A Mulford
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 458, New York, NY 10021, USA
    Expert Opin Biol Ther 4:95-105. 2004
    ....
  24. ncbi Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience
    A Ganetsky
    Pharmacy Department, Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center, New York, NY Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 29:6593. 2011
    ..We conducted a retrospective analysis of the efficacy of decitabine in patients with AML treated at Memorial Sloan-Kettering Cancer Center (MSKCC)...
  25. ncbi Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL
    D D Shepard
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI Stanford Cancer Center, Stanford, CA Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY Loyola University Medical Center, Maywood, IL Loyola University Cancer Center, Maywood, IL Memorial Sloan Kettering Cancer Center, New York, NY University of Michigan Medical Center, Ann Arbor, MI
    J Clin Oncol 29:6619. 2011
    ..However, few series have assessed outcomes after ASCT following ATO reinduction. We performed a retrospective analysis of ATO followed by ASCT for pts with relapsed APL...
  26. ncbi Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML)
    J G Jurcic
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center, New York, NY Actinium Pharmaceuticals, Inc, Newark, NJ
    J Clin Oncol 29:6516. 2011
    ..sup>225Ac-labeled immunoconjugates kill in vitro at doses at least 1,000 times lower than 213Bi analogs and prolong survival in mouse xenograft models of several cancers...
  27. ncbi Cytomorphologic and clinical features of AML with translocation (8;16) mimicking APL
    S Jhanwar
    Memorial Sloan Kettering Cancer Center, New York, NY Dana Farber Cancer Institute and ECOG Statistical Center, Boston, MA Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY Montefiore Medical Center North Division, New York, NY
    J Clin Oncol 29:6626. 2011
    ..Furthermore t(8;16) AML is reported to be more frequently found among therapy-related AMLs, which may make it more relevant to the patient population treated at tertiary cancer centers...
  28. ncbi Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin
    Timothy B Aliff
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 97:1025-32. 2003
    ..The authors treated a group of patients with amphotericin-refractory IFIs with the combination of caspofungin and amphotericin (or liposomal amphotericin)...
  29. ncbi Antibody therapy in acute myeloid leukemia: current status and future directions
    John M Burke
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Lymphoma 2:S12-8. 2002
    ..Directed chemotherapy using the anti-CD33-calicheamicin conjugate gemtuzumab ozogamicin (Mylotarg) has produced remissions in patients with relapsed AML...
  30. ncbi A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia
    Mark A Weiss
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer 95:581-7. 2002
    ..The authors studied a regimen that contained high-dose cytarabine and a single high dose of idarubicin as salvage induction therapy for patients with recurrent or refractory lymphoblastic disease...